UroGen Pharma Ltd. Ordinary Shares - URGN STOCK NEWS

UroGen Pharma (Nasdaq: URGN) has announced the grant of inducement restricted stock units (RSUs) and an option to 15 new employees, including Chief Commercial Officer David Lin. Up to 52,500 shares will be issued upon vesting for 14 employees, and up to 13,041 shares plus 71,942 shares upon the exercise of an option will be issued for Lin. RSUs and options vest over three years, contingent on continued employment. The exercise price for the option is set at $13.13, the closing price on June 3, 2024. These grants are under UroGen's 2019 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4), to support the commercialization of Jelmyto and pipeline development.

UroGen Pharma (Nasdaq: URGN) will host a virtual event on June 13, 2024, at 11:00 a.m. ET, to present the 12-month durability response results from its Phase 3 ENVISION trial. This trial assesses UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The focus will be on patients who showed a complete response at three months after six weekly doses. The event will include insights from Key Opinion Leaders and a panel discussion. A replay will be available on the company's website after the event.

UroGen Pharma (Nasdaq: URGN) announced its participation in the 45th Annual Goldman Sachs Global Healthcare Conference. The event will occur in Miami, FL, from June 10-13, 2024, and UroGen's management will present on June 11 at 3:20 PM ET. The presentation will be in a fireside chat format. A webcast will be available live and for replay for approximately 90 days on the company's investor relations website.

UroGen Pharma (NASDAQ: URGN) has appointed David Lin as the new Chief Commercial Officer. Lin, who boasts extensive experience from Bristol Myers Squibb and other significant roles in the pharmaceutical industry, will lead UroGen's commercial strategy. His key responsibilities include preparing for the potential launch of UGN-102 and enhancing the commercialization of JELMYTO® (mitomycin). Lin's background includes successful launches of CAR T therapies and global expansion initiatives. Jeff Bova, the former CCO, will step down on June 3 to pursue new opportunities.

UroGen Pharma (Nasdaq: URGN), a biotech firm focused on urothelial and specialty cancers, will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2024, at 3:20 PM ET. Investors can access a live webcast through the company's website. This event presents an opportunity for UroGen to discuss its innovative cancer treatments and engage with stakeholders.

UroGen Pharma announced ENVISION study data, JELMYTO durability results, and financials for Q1 2024. JELMYTO net sales grew to $18.8 million, IND accepted for UGN-103, and UGN-102 NDA expected in Q3 2024. JELMYTO post-hoc analysis showed a median disease-free period of 47.8 months in LG-UTUC. UroGen also entered a licensing agreement for next-gen mitomycin-based UGN-103 to treat urothelial cancers.

UroGen Pharma (URGN) is set to participate in upcoming investor conferences like Citizens JMP Life Sciences Conference and H.C. Wainwright BioConnect Conference in May 2024. The company aims to present its innovative solutions for urothelial and specialty cancers, showcasing its commitment to developing and commercializing effective treatments.

UroGen Pharma has presented a real-world retrospective analysis at AUA 2024, reporting an 86% Recurrence-Free Survival (RFS) at 24 months with JELMYTO® for patients with low-grade Ta upper tract urothelial carcinoma who were complete responders to induction therapy. No differences in RFS were found based on treatment usage, tumor characteristics, or timing of administration. Patients who received maintenance therapy showed a 100% RFS at 24 months compared to 61% for those who did not receive maintenance therapy. These results suggest JELMYTO's potential in treating UTUC and improving long-term outcomes.

UroGen Pharma announced the results from the ATLAS trial, showing the durability of response in new and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer patients treated with UGN-102. The data revealed high probabilities of remaining in complete response for both patient groups, indicating the potential of UGN-102 as a primary treatment option. The Phase 3 ATLAS study demonstrated favorable Disease Free Survival and Durability of Response rates with UGN-102 compared to the standard treatment. These findings highlight the promise of UGN-102 in transforming the landscape of LG-IR-NMIBC treatment, potentially reducing the need for repetitive surgeries and their associated risks and burdens.